晚期糖基化终产物与冠心病发病机制的研究进展

doi:10.3969/j.issn.1673-8640.2014.01.019

摘要/Abstract

摘要： 晚期糖基化终产物(AGEs)密切参与了血管平滑肌细胞(VSMCs)分化与增殖以及冠心病等心血管疾病的病理生理过程。AGEs能通过单核细胞趋化蛋白(ERK)、丝氨酸/苏氨酸蛋白激酶(Akt)信号通路来诱导VSMCs的自噬作用, 可依赖骨髓基质细胞衍生因子-1(SDF-1)/趋化因子受体CXCR4轴信号通路促进心肌微血管内皮细胞(CMECs)的增生。AGEs-2和AGEs-3上调了单核细胞AGEs受体(RAGE)的表达。AGEs能抑制内皮祖细胞(EPCs)的增殖、迁移和黏附功能并诱导EPCs凋亡;能增加平滑肌细胞结缔组织因子(CTGF)mRNA和蛋白质的表达, 刺激心肌成纤维细胞增殖并分泌转化生长因子-β1(TGF-β1), 同时诱导Smad2及Smad4的表达。羧甲基赖氨酸(CML)/RAGE轴通过主动脉平滑肌成骨细胞的分化, 诱导巨噬细胞凋亡, 从而使AGEs在糖尿病动脉粥样硬化中发挥重要作用。可溶性RAGE(sRAGE)可作为RAGE配体的诱饵来防止动脉粥样硬化, 其灵敏度和阴性预测值在判定冠状动脉介入治疗(PCI)术后再狭窄方面均高于AGEs/ sRAGE比值。ALT-711是一种AGEs的裂解剂, 能明显抑制AGEs介导的活性氧(ROS)产生、细胞外信号调节激酶磷酸化及环氧合酶-2的表达;色素上皮衍生因子(PEDF)能抑制AGEs诱导的血小板CD40配体(CD40L)表达, 从而有可能成为预防冠心病的一个治疗靶点。他汀类药物亦能抑制AGEs诱导主动脉平滑肌细胞的增殖及ROS的产生。通过以上诸多因素的研究, 可揭示冠心病的某些发病机制, 为相应干预药物的研究及调整临床治疗策略提供依据和方向。

关键词: 晚期糖基化终产物, 晚期糖基化终产物受体, 冠心病, 动脉粥样硬化, 血管平滑肌细胞, 信号传导

Abstract: Advanced glycation end products (AGEs) are closely involved in the pathophysiological process of vascular smooth muscle cell (VSMCs) differentiation, proliferation, coronary artery disease and other cardiovascular diseases. AGEs can induce autophagy in VSMCs through the extracellular signal-regulated protein kinase(ERK) and serine-threonine kinase (Akt) signaling pathways. AGEs improve cardiac microvascular endothelial cell (CMECs) proliferation depending on bone marrow stromal cell-derived factor-1(SDF-1)/ chemokine receptor CXCR4 axis signaling pathway. AGEs-2 and AGEs-3 up-regulate the expression of receptor for advanced glycation end product (RAGE) on monocytes. AGEs inhibit the proliferation, migration and adhesion of endothelial progenitor cell (EPCs), and induce the apoptosis of EPCs. AGEs increase the expression activity of connective tissue growth factor(CTGF) mRNA and protein, and promote the proliferation of cardiac fibroblast and the secretion of transforming growth factor-beta 1 (TGF-β1) and induce the expressions of Smad2 and Smad4. The carboxymethyl lysine(CML)/RAGE axis plays an important role in atherosclerotic calcification of diabetes through the mechanism that induces the apoptosis of macrophages followed by the osteogenic differentiation of aortic smooth muscle cells. Soluble form of RAGE(sRAGE) can be served as bait of RAGE ligand to prevent atherosclerosis, and the sensitivity and negative predictive value of sRAGE are higher than those of AGEs/sRAGE ratio in identifying post-percutaneous coronary intervention (PCI) restenosis. ALT-711 is a breaker of AGEs-based cross links, which can inhibit AGEs-mediated formation of reactive oxygen species (ROS), extracellular signal-regulated kinase phosphorylation and cyclooxygenase-2 expression. Pigment epithelium-derived factor (PEDF) can inhibit CD40 ligand(CD40L) overexpression by blocking the effects of AGEs on platelets, which may become a therapeutic target for the prevention of coronary artery disease. Statins can also inhibit AGEs-induced aortic smooth muscle cell proliferation and production of ROS. The research above can reveal some the pathogenesis of coronary artery disease, provide foundation and direction for exploring the corresponding drug intervention and adjustment of clinical treatment strategies.

Key words: Advanced glycation end product, Receptor for advanced glycation end product, Coronary artery disease, Atherosclerosis, Vascular smooth muscle cell, Signal transduction

中图分类号:

R446.1

刘军锋, 孔美娟, 贾克刚. 晚期糖基化终产物与冠心病发病机制的研究进展[J]. 检验医学, 2014, 29(1): 76-80.

LIU Junfeng, KONG Meijuan, JIA Kegang.. Research on advanced glycation end products in the mechanism of coronary artery disease[J]. , 2014, 29(1): 76-80.

参考文献

[1] Prasad A, Bekker P, Tsimikas S. Advanced glycation end products and diabetic cardiovascular disease[J]. Cardiol Rev, 2012, 20(4): 177-183.
[2] Hu P, Lai D, Lu P, et al. ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells[J]. Int J Mol Med, 2012, 29(4): 613-618.
[3] Xie Y, You SJ, Zhang YL, et al. Protective role of autophagy in AGE-induced early injury of human vascular endothelial cells[J]. Mol Med Report, 2011, 4(3): 459-464.
[4] 粟妍晖, 李飞, 王冬娟, 等.AGEs通过SDF-1/CXCR4轴信号通路对心肌微血管内皮细胞血管新生的影响及机制[J].现代生物医学进展, 2010, 10(7):1270-1272.
[5] Takahashi HK, Mori S, Wake H, et al. Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells[J]. J Pharmacol Exp Ther, 2009, 330(1): 89-98.
[6] 何榕, 毛节明, 王广, 等.晚期糖基化终产物对大鼠血管平滑肌细胞分泌炎症性趋化因子的影响及机制[J].中华医学杂志, 2011, 91(2):107-110.
[7] 李贵星, 贺勇, 吕瑞雪, 等.糖尿病患者血清糖化低密度脂蛋白水平研究[J].检验医学, 2010, 25(8):588-591.
[8] Ueda S, Yamagishi S, Matsui T, et al. Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects[J]. Cardiovasc Ther, 2012, 30(4): 249-254.
[9] Chen J, Song M, Yu S, et al. Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress[J]. Mol Cell Biochem, 2010, 335(1-2): 137-146.
[10] Nam MH, Lee HS, Seomun Y, et al. Monocyte-endothelium-smooth muscle cell interaction in co-culture: proliferation and cytokine productions in response to advanced glycation end products[J]. Biochim Biophys Acta, 2011, 1810(9): 907-912.
[11] Xanthis A, Hatzitolios A, Fidani S, et al. Receptor of advanced glycation end products (RAGE) positively regulates CD36 expression and reactive oxygen species production in human monocytes in diabetes[J]. Angiology, 2010, 60(6):772-779.
[12] 顾秀峰, 张寰, 刘勇, 等.糖基化终产物对大鼠主动脉平滑肌细胞结缔组织生长因子表达的影响[J].中华老年医学杂志, 2009, 28(10): 847-850.
[13] 李洁, 刘乃丰, 魏芹.罗格列酮抑制糖基化终产物诱导心肌成纤维细胞增殖和结缔组织生长因子及Smad的表达[J].中华内分泌代谢杂志, 2010, 26(6): 479-483.
[14] Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease[J]. Expert Rev Mol Med, 2009, 11: e9.
[15] Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes[J]. Clin Sci (Lond), 2011, 121(2): 43-55.
[16] Walcher D, Marx N. Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis[J]. Semin Immunopathol, 2009, 31(1): 103-311.
[17] Wang Z, Jiang Y, Liu N, et al. Advanced glycation end-product N ε-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes[J]. Atherosclerosis, 2012, 221(2): 387-396.
[18] McNair ED, Wells CR, Mabood Qureshi A, et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention[J]. Clin Cardiol, 2010, 33(11): 678-685.
[19] Kim JB, Song BW, Park S, et al. Alagebrium chloride, a novel advanced glycation end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model[J]. Korean Circ J, 2010, 40(10): 520-526.
[20] Krautwald M, Leech D, Horne S, et al. The advanced glycation end product-lowering agent ALT-711 is a low-affinity inhibitor of thiamine diphosphokinase[J]. Rejuvenation Res, 2011, 14(4): 383-391.
[21] Yamagishi S, Matsui T, Ueda S, et al. Pigment epithelium-derived factor (PEDF) inhibits diabetes- or advanced glycation end product (AGE)-induced platelet CD40 ligand overexpression in rats[J]. Int J Cardiol, 2010, 144(2): 283-285.
[22] Yoon SJ, Yoon YW, Lee BK, et al. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy[J]. Exp Mol Med, 2009, 41(11): 802-811.
[23] 徐尚华, 王科峰, 许昌声, 等.阿托伐他汀对晚期糖基化终末产物诱导的人内皮细胞单核细胞趋化蛋白-1 mRNA表达影响极其机制的实验研究[J].中华心血管病杂志, 2011, 39(6): 512-517.